Risk factors
CorMedix (CRMD) risk factors
Item 1A of every CorMedix Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors32 risks14 new10 dropped13 reworded
CorMedix turned profitable in 2025 with $163.1 million in net income, reducing its accumulated deficit to $176.6 million.
Filed Mar 05, 2026 - FY2024 10-K risk factors28 risks
Commercialization of DefenCath dominates risk, alongside heavy customer concentration, accumulated deficits, and outsourced manufacturing dependencies.
Filed Mar 25, 2025